Patent ID: 9555137
Date: 2017-01-31
CPC Classifications: A61K,A61P,G01N

Claim:
1. A method for determining whether a patient with a blood cancer will likely respond to therapy with an HSP90 inhibitor which comprises: (a) contacting a sample containing blood cancer cells and non-cancerous blood cells from the patient with a cell permeable fluorescently labeled HSP90 inhibitor that binds directly and preferentially to a cancer-specific form of HSP90 present in the cancer cells of the patient; (b) measuring the amount of fluorescently labeled HSP90 inhibitor bound to HSP90 protein in the cancer cells and non-cancer cells in the sample; and (c) comparing the amount of the fluorescently labeled HSP90 inhibitor bound to the cancer cells with the amount of the fluorescently labeled HSP90 inhibitor bound to the non-cancer cells, wherein a greater amount of fluorescently labeled HSP90 inhibitor bound to the cancer cells than the non-cancer cells indicates presence of the cancer specific form of HSP90 in the cancer cells; thereby determining that the blood cancer will likely respond to therapy with the HSP90 inhibitor.